间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题，原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胃癌免疫治疗：2021 年更新
英文原题：Immunotherapy for gastric cancer: a 2021 update.
查看英文原题
Immunotherapy for gastric cancer: a 2021 update.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胃癌是全球第五大常见癌症和第四大癌症死亡原因，死亡率极高。由于大多数胃癌患者确诊时已处于晚期，不适合手术，表现为局部晚期或转移性疾病。近年来免疫治疗的进展作为多种癌症类型的可行治疗选择引起了广泛关注。本文总结了目前正在进行的临床试验，并批判性地探讨了广泛免疫治疗方法在胃癌普通人群中的疗效及其与肿瘤基因图谱的关系。
展开英文摘要原文
Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer are diagnosed at advanced stages, they are not suitable for surgery and present with locally advanced or metastatic disease.
Recent advances in immunotherapy have elicited a considerable amount of attention as viable therapeutic options for several cancer types. This work presents a summary of the currently ongoing clinical trials and critically addresses the efficacy of a large spectrum of immunotherapy approaches in the general population for gastric cancer as well as in relation to tumor genetic profiling.
论文信息
- 作者
- Kole C、Charalampakis N、Tsakatikas S、Kouris NI、Papaxoinis G、Karamouzis MV、Koumarianou A、Schizas D
- 单位
- First Department of Surgery, National & Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece.Greece
- 文献类型
- 综述
- 期刊
- Immunotherapy2022 Jan
- 原文标识
- PubMed 34784774 · DOI 10.2217/imt-2021-0103